Key result
KN62 dose-dependently inhibited K(+)- and AII-stimulated aldosterone production, producing 93.9% and 82.3% inhibition at 10 microM (both p < 0.01), but exhibited non-specific inhibitory effects.
Population
Human adrenocortical tumor cell line (H295R)
Comparison
KN62 vs Control/basal conditions, nifedipine, and KNO4
Design
Preclinical
Authors
Loading...
KN62's non-specific aldosterone inhibition in H295R cells cautions against its use as selective CaMKII probe; leaves open need for specific inhibitors in research.
p-value: p=< 0.01
KN62 exhibits non-specific inhibitory effects on aldosterone secretion in H295R cells, limiting its utility as a specific CaM kinase II inhibitor in this model.
Clyne et al. (1995) studied Adrenocortical tumor cell line (H295R). KN62 was evaluated on Inhibition of K(+)- and AII-stimulated aldosterone production (p=< 0.01). KN62 dose-dependently inhibited K(+)- and AII-stimulated aldosterone production, producing 93.9% and 82.3% inhibition at 10 microM (both p < 0.01), but exhibited non-specific inhibitory effects.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: